Sesen Bio Inc.

NASDAQ:SESN   2:51:11 PM EDT
1.16
+0.02 (+1.75%)
Earnings Announcements

Sesen Bio Reports Third Quarter 2020 Financial Results

Published: 11/09/2020 14:25 GMT
Eleven Biotherapeutics Inc (SESN) - Sesen Bio Reports Third Quarter 2020 Financial Results and Positive Progress Towards Completing the Bla Submission for Vicineumtm in December 2020.
Q3 Revenue $11.2 Million.
Q3 Revenue Estimate $0 -- Refinitiv Ibes Data (analyst estimates).
Qtrly Net Loss Was $22.6 Million, Or $0.19 per Basic Share and Diluted Share.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.09

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.08

More details on our Analysts Page.